Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
10 January 2023 - 12:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2023
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its
Charter)
Tuborg Boulevard 12
DK-2900
Hellerup
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the
Form 6-K in paper
as permitted by Regulation S-T Rule
101(b)(1): ☐
Indicate by check mark if the registrant is submitting the
Form 6-K in paper
as permitted by Regulation S-T Rule
101(b)(7): ☐
Spokespersons of Ascendis Pharma A/S (the “Company”) plan to
present the information in the presentation slides attached hereto
as Exhibit 99.1 at various investor and analyst meetings scheduled
during the week of January 9, 2023.
The furnishing of the attached presentation and press release is
not an admission as to the materiality of any information therein.
The information contained in the presentation and press release is
summary information that is intended to be considered in the
context of more complete information included in the Company’s
filings with the Securities and Exchange Commission (the “SEC”) and
other public announcements that the Company has made and may make
from time to time. The Company undertakes no duty or obligation to
update or revise the information contained in this report, although
it may do so from time to time as its management believes is
appropriate. Any such updating may be made through the filing or
furnishing of other reports or documents with the SEC or through
other public disclosures.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
Ascendis Pharma A/S |
|
|
|
|
Date: January 9, 2023 |
|
|
|
By: |
|
/s/
Michael Wolff Jensen |
|
|
|
|
|
|
Michael Wolff Jensen |
|
|
|
|
|
|
Senior Vice President, Chief Legal Officer |
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Mar 2023 to Apr 2023
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2022 to Apr 2023